Search

BioNTech SE ADR

Закрыт

СекторЗдравоохранение

92.98 0.85

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

89.88

Макс.

93.19

Ключевые показатели

By Trading Economics

Доход

-294M

-834M

Продажи

-13M

107M

Прибыль на акцию

-3.03

Рентабельность продаж

-777.273

Сотрудники

7,807

EBITDA

-32M

-482M

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+33.83% upside

Дивиденды

By Acuity

Следующий отчет о доходах

3 нояб. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

-17M

23B

Предыдущая цена открытия

92.13

Предыдущая цена закрытия

92.98

Новостные настроения

By Acuity

19%

81%

51 / 340 Рейтинг в Healthcare

BioNTech SE ADR График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

14 авг. 2026 г., 19:26 UTC

BioNTech SE shares are higher today, continuing an upward trend since Thursday. This movement occurs despite concerns over declining U.S. retail sales data.

13 авг. 2026 г., 19:21 UTC

News

BioNTech SE shares are lower as analysts adjust price targets following a significant second-quarter revenue decline and a net loss of €820.8 million.

12 авг. 2026 г., 19:26 UTC

Correlated Moves

BioNTech SE's shares are higher today, supported by a significant rise in Moderna Inc. amid optimistic market sentiment following recent inflation data.

11 авг. 2026 г., 20:06 UTC

BioNTech SE shares are near unchanged amid a flat market performance. The stock remains above its 20-day moving average and near the upper end of its one-month range.

10 авг. 2026 г., 21:01 UTC

BioNTech SE shares are higher in after-market trading, showing stability despite broader market conditions and weaker-than-expected job growth data.

7 авг. 2026 г., 19:56 UTC

News
Correlated Moves

BioNTech SE is trading higher, likely influenced by Moderna's significant gains. The stock remains above its 20-day moving average despite recent revenue declines.

6 авг. 2026 г., 19:51 UTC

News
Correlated Moves

BioNTech SE shares are lower amid negative sentiment in the Biotechnology sector, following a revenue decline and CEO transition announcement.

5 авг. 2026 г., 19:32 UTC

News

BioNTech SE shares are higher today after Citigroup maintained its Buy rating, lowering its price target to $125 while Evercore ISI kept its Outperform rating at $130.

4 авг. 2026 г., 20:03 UTC

News
Social Media

BioNTech SE reported a widened second-quarter loss and lowered 2026 revenue guidance, contributing to shares trading lower since Monday's close.

3 авг. 2026 г., 21:01 UTC

BioNTech SE shares are lower in after-market hours, showing little movement despite a broader market rally and investor optimism from lower oil prices.

31 июл. 2026 г., 19:16 UTC

Correlated Moves

BioNTech SE shares are lower today, pressured by broader market sentiment and a decline in Moderna Inc. The stock remains below its 20-day moving average.

30 июл. 2026 г., 21:01 UTC

BioNTech SE shares are trading lower in after-market hours, reversing earlier gains and reflecting notable volatility without any specific news to explain the movement.

29 июл. 2026 г., 19:55 UTC

BioNTech SE shares are advancing during Wednesday's session, reaching a session high earlier today before pulling back slightly. No specific news was identified.

28 июл. 2026 г., 19:16 UTC

BioNTech SE shares are advancing today, rebounding from earlier lows. The stock's resilience contrasts with declines in the Nikkei 225 Index.

27 июл. 2026 г., 19:06 UTC

BioNTech SE shares are higher today amid positive market sentiment, reaching a peak earlier. No specific news has been identified to explain the movement.

24 июл. 2026 г., 19:06 UTC

BioNTech SE shares are lower today, continuing a decline amid broader market pressure and a significant drop in crude oil prices.

22 июл. 2026 г., 18:06 UTC

BioNTech SE shares are lower today, reflecting broader market caution amid rising crude oil prices and geopolitical tensions ahead of major technology earnings reports.

21 июл. 2026 г., 14:41 UTC

News

BioNTech SE is rising amid positive market sentiment and plans to report second-quarter 2026 results on August 4, 2026. The Nasdaq 100 Index is also up.

20 июл. 2026 г., 19:06 UTC

News

BioNTech SE shares are higher today, supported by a positive analyst outlook and an average recommendation of "Moderate Buy" from nineteen brokerage firms.

Сравнение c конкурентами

Изменение цены

BioNTech SE ADR Прогноз

Целевая цена

By TipRanks

33.83% рост

Прогноз на 12 месяцев

Средняя 124.58 USD  33.83%

Максимум 142 USD

Минимум 92 USD

Основано на мнении 12 аналитиков Wall Street, спрогнозировавших целевые цены для BioNTech SE ADR на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

12 ratings

10

Покупка

2

Удержание

0

Продажа

Настроения

By Acuity

51 / 340Рейтинг в Здравоохранение

Новостные настроения

Сильные свидетельства восходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Ниже среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании BioNTech SE ADR

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A, as well as strategic partnership the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen africa's mrna vac
help-icon Live chat